Le Lézard
Classified in: Health, Business
Subject: LIC

Goldfinch Bio Announces Collaborations with Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to Augment World's Largest Genomic Registry of Patients with Kidney Disease



CAMBRIDGE, Mass., Oct. 17, 2017 /PRNewswire/ -- Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced collaborations with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients with proteinuric kidney disease. The collaborations will integrate genomic analysis and de-identified clinical data from Mount Sinai's BioMe BioBank and Vanderbilt's BioVU BioBank to expand Goldfinch's Patient Registry, generating an unparalleled collection of insights from patients with kidney disease.

Goldfinch Bio is leading a new age of therapeutic discovery and development in the kidney space, and is building the world's largest genomic registry of patients with kidney disease to inform new disease targets, pathways, and biomarkers for the discovery and development of novel therapies. The patient registry is a key component of the company's integrated product engine, which will drive breakthroughs in genetics and biology to bring precision medicines to patients with kidney disease.

In October 2017, Goldfinch announced the Company's foundational patient registry collaboration with The Nephrotic Syndrome Study Network (NEPTUNE), a network of academic centers focused on clinical and translational research on kidney diseases presenting as Nephrotic Syndrome. The collaborations with Mount Sinai and Vanderbilt University Medical Center build upon this foundation, creating a comprehensive, federated database that integrates patient clinical data with molecular characterization at the DNA, RNA, and protein level. 

"We are thrilled to work with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to advance our understanding of the molecular pathways of kidney disease and bring precision medicines to patients," stated Abbie Celniker, Ph.D., interim chief executive officer of Goldfinch.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.

Goldfinch Bio Contact
Jennifer Williams
Cook Williams Communications, Inc.
jennifer@cwcomm.org
360-668-3701

 

SOURCE Goldfinch Bio


These press releases may also interest you

at 12:33
BOCA RATON, FL--(Marketwired - November 17, 2017) - Bluegreen Vacations Corporation ("Bluegreen Vacations" or "Bluegreen") (NYSE: BXG), announced today that its Common Stock commenced trading on the New York Stock Exchange ("NYSE") under the ticker...

at 12:33
PIMCO Global Income Opportunities Fund Announces Monthly Distribution Not for distribution to United States newswire services or for dissemination in the United States TORONTO, Nov. 17, 2017 (GLOBE NEWSWIRE) -- PIMCO Global Income...

at 12:33
FORT LAUDERDALE, FL--(Marketwired - November 17, 2017) - BBX Capital Corporation (NYSE: BBX) (OTCQX: BBXTB) ("BBX Capital" or the "Company") today announced that Bluegreen Vacations Corporation's (NYSE: BXG) ("Bluegreen Vacations" or "Bluegreen")...

at 12:30
Western Innovation Initiative funding will help turn Edmonton's garbage into energy EDMONTON, Nov. 17, 2017 /CNW/ - Enerkem Alberta Biofuels, a subsidiary of Montreal-based Enerkem Inc., is receiving $3.5 million from the Government of Canada...

at 12:15
SINGAPORE, Nov. 17, 2017 /PRNewswire/ -- The largest B2B & B2C event Forex & Money EXPO organized by FINEXPO is going to take place on Oct. 25-26, 2018 at Suntec Singapore Convention & Exhibition Centre. Forex & Money EXPO is about to become the...

at 12:06
DENVER, Nov. 17, 2017 /PRNewswire/ -- Despite record low inventory for the month, October home sales increased 2.5% year-over-year and kept 2017 prices ahead of 2016, according to this month's RE/MAX National Housing Report. To access the housing...




News published on 17 october 2017 at 07:30 and distributed by: